Amgen/Horizon Therapeutics: Judge Kness’s Criminal Law Background, Willingness to Get into Market Detail May Offset His Federalist Society Credentials

Published on Jun 01, 2023

The FTC’s suit to block Amgen’s (AMGN) $27.8 billion acquisition of Horizon Therapeutics (HZNP) rests on tenets of antitrust law that U.S. antitrust enforcers haven’t used to challenge a merger in decades, prompting a skeptical response from defense attorneys and veteran deal watchers alike. The agency might consider it a blessing, then, that the federal […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.